Hello - has anyone here heard of the Dezawa Exosomes? They are being produced and administered in Mexico. Maria Dezawa has produced human clinical trials in Japan showing safety and efficacy.
My question is can any lab guarantee the viability of the cells? The exosome treatment sounds too good to be true so therefore….it probably is. I’m very close to experimenting with going to Mexico and taking the Dezawa Exosomes for my arthritis and other joint pain.
Does anyone else have information on this subject?
Here’s what’s out there on “Dezawa exosomes” (i.e., exosomes derived from Dr. Mari Dezawa’s MUSE cells):
What they are
MUSE cells (Multilineage-Differentiating Stress-Enduring cells) are a rare SSEA-3⁺, pluripotent-like, endogenous stem cell population discovered by Prof. Mari Dezawa (Tohoku Univ.). They are stress-resistant, non-tumorigenic, and present within MSC preparations and multiple tissues. (PMC)
“Dezawa exosomes” refers (in marketing and some patents) to exosomes/EVs harvested from MUSE cells rather than bulk MSCs, with the claim that they carry distinct, more regenerative cargo. The concept appears in company materials and a recent hypothesis paper; formal peer-reviewed primary data remain sparse. (MUSECell Innovations®)
Evidence base (what’s actually published)
Peer-reviewed, MUSE-exosome–specific literature: as of 2025, largely conceptual. A 2025 hypothesis article proposes that MUSE-derived exosomes could provide a safe, scalable cell-free therapy, but it does not present clinical or robust in-vivo efficacy data for MUSE exosomes. (PubMed)
Related MUSE cell data (not exosomes): Multiple reviews and preclinical studies describe MUSE cells’ reparative properties (stroke, myocardial infarction, neuroinflammation), including recent work and overviews from Dezawa’s group; these support the parent cell’s potential but do not establish distinct clinical benefits for its exosomes yet. (PMC)
Patents: A 2023–2025 patent family from Dezawa-affiliated inventors details methods to enrich MUSE cells and obtain their exosomes/microvesicles/secretome, indicating an intent to commercialize MUSE-exosome production; patents are not evidence of efficacy. (Google Patents)
Claims you’ll see (and how solid they are)
Regeneration / “pluripotent signals”: Company/clinic sites claim MUSE exosomes carry “pluripotent-like regenerative signals,” superior to MSC exosomes. These are marketing claims; they lack head-to-head, peer-reviewed comparative data. (Eterna Health)
Mechanisms (hypothesized): Like other stem-cell exosomes, they would deliver miRNAs/proteins for immunomodulation, anti-inflammation, and repair; this is extrapolated from MUSE-cell biology and the broader MSC-exosome literature, not uniquely demonstrated for MUSE exosomes. (PubMed)
Regulation & clinical status
No FDA approvals for any human MUSE-exosome therapeutic/cosmetic product. (General reporting notes exosomes in skincare are unregulated and controversial.) (WIRED)
Regulatory cautions: In the UK and EU, human-origin exosomes used in cosmetics are banned; enforcement actions/reporting highlight safety and contamination risks and difficulties distinguishing exosomes from viruses. (The Guardian)
Clinical trials: There are ongoing/reported trials and preclinical work with MUSE cells, including novel routes like intranasal delivery for stroke, but not clinical trials specifically of MUSE-derived exosomes as a distinct product that are indexed in the literature. (Nature)
How MUSE exosomes differ (in theory) from MSC exosomes
Cell of origin: MUSE cells are a distinct, reparative SSEA-3⁺ subset within MSCs; proponents argue their EV cargo could be more reparative and less variable than bulk-MSC EVs. Evidence to prove consistent superiority is not yet published. (PMC)
IP & standardization: Specific enrichment/production methods are described in patents, aiming at standardized MUSE-exosome products; peer-reviewed manufacturing/quality control data are not yet broadly available. (Google Patents)
Practical takeaways (as of Oct 25, 2025)
State of the science: MUSE cells have growing preclinical/early translational evidence; MUSE-derived exosomesare promising but still hypothetical in peer-reviewed literature. Treat bold efficacy claims with caution until comparative, controlled data are published. (PMC)
Buyer-beware: Clinics and websites advertising “Dezawa MUSE exosome” therapies are operating ahead of clear regulatory authorization; vet any offering rigorously. (Eterna Health)
Watch-list items to track: (1) first in-vivo studies isolating and testing MUSE-exosome pharmacology vs. MSC exosomes; (2) omics of MUSE-exosome cargo; (3) GMP manufacturing/lot consistency; (4) safety (sterility, endotoxin, residual DNA/viral exclusion); (5) regulatory guidance/approvals. (Rationale based on field concerns.) (WIRED)
Here’s the freshest, citable roundup focused on MUSE-derived (“Dezawa”) exosomes—preprints, patents/assignments, and any trial-registry signals—through Oct 25, 2025:
What’s new in the literature/preprints
Hypothesis paper (2025, Stem Cell Reviews & Reports): argues for a cell-free therapeutic platform using MUSE cell-derived exosomes; proposes validation frameworks but presents no in-vivo efficacy for MUSE exosomes yet. (PubMed)
Recent MUSE overviews (not exosome-specific): Dezawa’s 2025 perspective and other reviews summarize MUSE biology/clinical cell data; they do not provide head-to-head data showing MUSE exosomes outperform MSC exosomes. (Frontiers)
MSC-exosome clinical context (comparators): active clinical trials and recent RCTs exist for MSC exosomes (various indications), underscoring field momentum—but none are specific to MUSE exosomes. (ClinicalTrials)
Patents & assignments (2023–2025)
Core family (PCT → US/EP/MX): “Method for enriching Muse cells and obtaining exosomes/microvesicles/secretome” describes (i) enrichment steps to yield high-MUSE cultures, (ii) production/harvest of EVs, and (iii) compositions, proposed dose ranges, stability, and broad indications (e.g., rosacea, melasma, osteoarthritis, psoriasis). Family includes WO2023164241A1 → EP4486307A1, US20250170183A1, MX2024010560A. (Note: PCT shows “ceased”; national filings continue.) (Google Patents)
Example claim details: EV sizing (exosome/microvesicle windows), source tissues (UC/Wharton’s jelly, placenta), surface markers (SSEA-3±CD105±CD90/CD73), concentration bands (10^5–10^10 EVs/mL), lyophilization stability (≤36 months), and repeated harvest schema. (Google Patents)
Older Dezawa/MUSE IP (cells, not EVs): foundational methods for MUSE cell isolation/expansion remain part of the IP landscape informing exosome sourcing. (Google Patents)
Trial registries
No clinical trials explicitly registered for “MUSE exosomes.” Searches across ClinicalTrials.gov and meta-portals return MSC-exosome trials only (e.g., endothelial dysfunction post-preeclampsia; dermatologic use), reinforcing that MUSE-exosome products have not yet reached registry-listed testing. (ClinicalTrials)
Company/clinic claims (2025): multiple sites advertise “Dezawa MUSE Exosomes” with anti-aging/immune or performance messaging; these are promotional and not peer-reviewed. (Clinic X)
MCI (licensing hub) positions “Dezawa MUSE Cells®” and their exosomes as standardized IP-backed products; site states findings pertain only to cells prepared under licensed methods. (Again, not peer-reviewed head-to-head exosome data.) (MUSECell Innovations®)
Conference mentions (Oct 2025): event recap lists a talk: “MUSE Cells™ and Their Exosomes: The Next Frontier in Immune-Modulating Therapies.” This is program content, not published data. (Global Stem Cells Group)
Bottom line (as of Oct 25, 2025)
Peer-reviewed evidence specific to MUSE-derived exosomes remains preliminary (conceptual/hypothesis). There are no registered clinical trials uniquely testing MUSE exosomes, and no comparative efficacy papers versus standard MSC exosomes. (PubMed)
IP is advancing: detailed manufacturing/characterization claims for MUSE-EVs are now public across US/EU filings—useful for understanding intended specs (markers, sizes, concentrations, stability). (Google Patents)
Marketing is ahead of data: clinic and aggregator sites promote “Dezawa MUSE exosomes,” but treat as unverified until independent omics, potency assays, and controlled studies appear. (Clinic X)
I have never heard of Dezawa Exosomes. I’ve heard mixed reviews on people’s experience with various cell therapies around the world.
If $ is not an issue, it might be worth it. However, one could get and try a lot of good medications for arthritis and joint pain, that might even work better.
You could write a list of what you have tried so far so people can give you other ideas here.
Look into Pentosan Polysulfate for joint issues.
Bisphosphonates might help, and they are rated very high on various longevity lists also.
Glucosamine and chondroitin are something to consider as they are also rated high in longevity lists and might help your condition.
Various anabolic hormones like nandrolone, testosterone. Various Monoclonal antibodies.
GLP-1’s might help. LDN (low dose naltrexone). NSAID’s, some were rated good for longevity.
Probably other good stuff on the market.
Price all these meds against the cell therapy, and see what’s the better cost to performance option.
Thank you for the info. I did already get more or less the same information from my own search. There is no guarantee that the Exosomes will actually deliver what they promise. There is no medical or scientific body in Mexico examining and holding accountable the clinic administering the cells and therefore, no guarantee that the product contains what they say it contains. Matt Kaberlein continues to disparage anyone who is willing to pay thousands of dollars for a product that may do no harm- maybe help - but could possibly be very dangerous. Yet - many stories of relief from pain I have heard from Joe Rogan to Mel Gibson, touting the benefits of stem cell therapy. The fact that Ken Ford is now on the board of the Muse Cell Innovations leads me to believe there is a very good potential for efficacy and safety from these cells. I’m assuming there is more interest in his part as to the drug delivery possibilities of exosomes rather than the purported healing of exosomes themselves…Does anyone know a good source for true information on the delivery of these cells? Where is the research now in the US? Are we close to allowing this therapy here? How can anyone take these cells in a country like Mexico without any controls??
And then on another note - Rhonda Patrick claims there is no benefit to taking Rapamycin if one is already eating a healthy diet (whole foods), at a healthy weight, exercises regularly with hit cardio, lifts weights and prioritizes sleep. What is the benefit?? I am already doing those things and there appears to be no way to measure benefits of Rapa - why take it??
That’s true, there may be no benefit if you are able to keep m-tor activation low via multiple lifestyle interventions. However you did fail to provide the most important determining factor…YOUR AGE (and presence of inflammatory conditions including signs of inflammaging)
Re exosomes/kimera: I agree. As an MD treating complex illness, me/cfs/lc I have seen significant benefit in about 60% of patients with exosomes tho usually require ongoing treatment, eg every 2-4 months. NO side effects. But definitely expensive. I only use Kimera exosomes.
